{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:43:25Z","timestamp":1792622605474,"version":"4.5.0"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T00:00:00Z","timestamp":1744502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100007052","name":"Universit\u00e0 degli Studi di Verona","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s40264-025-01548-3","type":"journal-article","created":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T12:16:51Z","timestamp":1744546611000},"page":"959-976","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance"],"prefix":"10.1007","volume":"48","author":[{"given":"Salvatore","family":"Crisafulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey Stuart","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Candore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Chandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek A.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith Christina","family":"Maro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Niklas","family":"Nor\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Pariente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulugeta","family":"Russom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maribel","family":"Salas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Segec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad","family":"Shakir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Spini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sengwee","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne","family":"van Puijenbroek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the Real-World Evidence\u00a0and Big Data Special Interest Group of the International Society of Pharmacovigilance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,13]]},"reference":[{"key":"1548_CR1","unstructured":"Council for International Organizations of Medical Sciences. Practical aspects of signal detection in pharmacovigilance. Report of CIOMS Working Group VIII. 2010. https:\/\/cioms.ch\/wp-content\/uploads\/2018\/03\/WG8-Signal-Detection.pdf."},{"key":"1548_CR2","unstructured":"Heads of Medicines Agencies (HMA), European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP). Module IX\u2014signal management (Rev 1). 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf."},{"key":"1548_CR3","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/00002018-200225060-00012","volume":"25","author":"SAW Shakir","year":"2002","unstructured":"Shakir SAW, Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford\u2013Hill criteria. Drug Saf. 2002;25:467\u201371.","journal-title":"Drug Saf"},{"key":"1548_CR4","doi-asserted-by":"crossref","unstructured":"Hammad TA, Afsar S, McAvoy LB, Le Louet H. Aspects to consider in causality assessment of safety signals: broadening the thought process. Front Drug Saf Regul. 2023. https:\/\/www.frontiersin.org\/journals\/drug-safety-and-regulation\/articles\/10.3389\/fdsfr.2023.1193413\/full.","DOI":"10.3389\/fdsfr.2023.1193413"},{"key":"1548_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/cpt.1426","volume":"106","author":"A Cave","year":"2019","unstructured":"Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019;106:36\u20139.","journal-title":"Clin Pharmacol Ther"},{"key":"1548_CR6","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/aje\/kwae035","volume":"193","author":"NA Dreyer","year":"2024","unstructured":"Dreyer NA, Blackburn SCF. Power to the people: why person-generated health data are important for pharmacoepidemiology. Am J Epidemiol. 2024;193:1215\u20138.","journal-title":"Am J Epidemiol"},{"key":"1548_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/cpt.3027","volume":"114","author":"P Anand","year":"2023","unstructured":"Anand P, Zhang Y, Merola D, Jin Y, Wang SV, Lii J, et al. Comparison of EHR data-completeness in patients with different types of medical insurance coverage in the United States. Clin Pharmacol Ther. 2023;114:1116\u201325.","journal-title":"Clin Pharmacol Ther"},{"key":"1548_CR8","unstructured":"European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP). ENCePP Guide on methodological standards in pharmacoepidemiology. Chapter 8: approaches to data collection. 2023. https:\/\/encepp.europa.eu\/encepp-toolkit\/methodological-guide\/chapter-8-approaches-data-collection_en."},{"key":"1548_CR9","unstructured":"Darwin EU. The Darwin EU\u00ae Data Network 2024. https:\/\/darwin-eu.org\/index.php\/data\/data-network."},{"key":"1548_CR10","unstructured":"European Medicines Agency (EMA). Data Analysis and Real World Interrogation Network (DARWIN EU). 2021. https:\/\/www.snds.gouv.fr\/SNDS\/Accueil."},{"key":"1548_CR11","unstructured":"Food and Drug Administration. FDA\u2019s sentinel initiative. 2024. https:\/\/www.fda.gov\/safety\/fdas-sentinel-initiative."},{"key":"1548_CR12","unstructured":"European Medicines Agency (EMA). Initiation of DARWIN EU\u00ae Coordination Centre advances integration of real-world evidence into assessment of medicines in the EU. 2022. https:\/\/www.ema.europa.eu\/en\/news\/initiation-darwin-eur-coordination-centre-advances-integration-real-world-evidence-assessment-medicines-eu."},{"key":"1548_CR13","unstructured":"Heads of Medicines Agencies (HMA), European Medicines Agency (EMA). HMA-EMA joint big data taskforce phase II report: \u201cEvolving Data-Driven Regulation.\u201d 2019."},{"key":"1548_CR14","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1002\/pds.4879","volume":"28","author":"M Yamaguchi","year":"2019","unstructured":"Yamaguchi M, Inomata S, Harada S, Matsuzaki Y, Kawaguchi M, Ujibe M, et al. Establishment of the MID-NET\u00ae medical information database network as a reliable and valuable database for drug safety assessments in Japan. Pharmacoepidemiol Drug Saf. 2019;28:1395\u2013404.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR15","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.therap.2016.02.016","volume":"71","author":"J-L Faillie","year":"2016","unstructured":"Faillie J-L, Montastruc F, Montastruc J-L, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016;71:211\u20136.","journal-title":"Therapie"},{"key":"1548_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s40259-021-00498-3","volume":"35","author":"G Trifir\u00f2","year":"2021","unstructured":"Trifir\u00f2 G, Isgr\u00f2 V, Ingrasciotta Y, Ientile V, L\u2019Abbate L, Foti SS, et al. Large-scale postmarketing surveillance of biological drugs for immune-mediated inflammatory diseases through an Italian distributed multi-database healthcare network: the VALORE Project. BioDrugs. 2021;35:749\u201364.","journal-title":"BioDrugs"},{"key":"1548_CR17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14712598.2024.2357381","volume":"24","author":"A Spini","year":"2024","unstructured":"Spini A, Pellegrini G, Ingrasciotta Y, L\u2019Abbate L, Bellitto C, Carollo M, et al. Switching patterns of biological drugs in patients with psoriasis and psoriatic arthritis: insight from the VALORE database network. Expert Opin Biol Ther. 2024;24:399\u2013409.","journal-title":"Expert Opin Biol Ther"},{"key":"1548_CR18","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2147\/CLEP.S314959","volume":"13","author":"K Laugesen","year":"2021","unstructured":"Laugesen K, Ludvigsson JF, Schmidt M, Gissler M, Valdimarsdottir UA, Lunde A, et al. Nordic health registry-based research: a review of health care systems and key registries. Clin Epidemiol. 2021;13:533\u201354.","journal-title":"Clin Epidemiol"},{"key":"1548_CR19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s10654-016-0117-y","volume":"31","author":"JF Ludvigsson","year":"2016","unstructured":"Ludvigsson JF, Almqvist C, Bonamy A-KE, Ljung R, Micha\u00eblsson K, Neovius M, et al. Registers of the Swedish total population and their use in medical research. Eur J Epidemiol. 2016;31:125\u201336.","journal-title":"Eur J Epidemiol"},{"key":"1548_CR20","unstructured":"Syst\u00e8me National des Donn\u00e9es de Sant\u00e9. The French National Healthcare Data System. 2023. https:\/\/www.snds.gouv.fr\/SNDS\/Accueil."},{"key":"1548_CR21","unstructured":"European Medicines Agency (EMA). Screening for adverse reactions in EudraVigilance. 2016. https:\/\/www.ema.europa.eu\/system\/files\/documents\/other\/wc500218606_en.pdf."},{"key":"1548_CR22","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/11586990-000000000-00000","volume":"34","author":"J Strandell","year":"2011","unstructured":"Strandell J, Caster O, Bate A, Nor\u00e9n N, Edwards IR. Reporting patterns indicative of adverse drug interactions: a systematic evaluation in VigiBase. Drug Saf. 2011;34:253\u201366.","journal-title":"Drug Saf"},{"key":"1548_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijmedinf.2015.10.005","volume":"86","author":"AM Walker","year":"2016","unstructured":"Walker AM, Zhou X, Ananthakrishnan AN, Weiss LS, Shen R, Sobel RE, et al. Computer-assisted expert case definition in electronic health records. Int J Med Inform. 2016;86:62\u201370.","journal-title":"Int J Med Inform"},{"key":"1548_CR24","doi-asserted-by":"crossref","unstructured":"Cutroneo PM, Sartori D, Tuccori M, Crisafulli S, Battini V, Carnovale C, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024. https:\/\/www.frontiersin.org\/journals\/drug-safety-and-regulation\/articles\/10.3389\/fdsfr.2023.1323057\/full.","DOI":"10.3389\/fdsfr.2023.1323057"},{"key":"1548_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-024-01404-w","volume":"47","author":"Y Noguchi","year":"2024","unstructured":"Noguchi Y, Yoshimura T. Detection algorithms for simple two-group comparisons using spontaneous reporting systems. Drug Saf. 2024;47:535\u201343.","journal-title":"Drug Saf"},{"key":"1548_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1002\/pds.3669","volume":"23","author":"L Van Holle","year":"2014","unstructured":"Van Holle L, Tavares Da Silva F, Bauchau V. Signal detection based on time-to-onset: extending a new method from spontaneous reports to observational studies. Pharmacoepidemiol Drug Saf. 2014;23:849\u201358.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR27","doi-asserted-by":"crossref","unstructured":"Gordillo-Mara\u00f1\u00f3n M, Szmigiel A, Yalmanov\u00e1 V, Caplanusi I, Genov G, Olsen DB, et al. COVID-19 vaccines and heavy menstrual bleeding: the impact of media attention on reporting to EudraVigilance. Drug Saf. 2024;47(8):783\u201398.","DOI":"10.1007\/s40264-024-01426-4"},{"key":"1548_CR28","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR29","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1046\/j.1365-2125.1999.00060.x","volume":"48","author":"IA Eland","year":"1999","unstructured":"Eland IA, Belton KJ, van Grootheest AC, Meiners AP, Rawlins MD, Stricker BH. Attitudinal survey of voluntary reporting of adverse drug reactions. Br J Clin Pharmacol. 1999;48:623\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"1548_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3233\/JRS-1992-3401","volume":"3","author":"SH Thomas","year":"1992","unstructured":"Thomas SH, Rawlins MD. Spontaneous reporting of fatal adverse drug reactions. Int J Risk Saf Med. 1992;3:179\u201381.","journal-title":"Int J Risk Saf Med"},{"key":"1548_CR31","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.jclinepi.2004.10.012","volume":"58","author":"S Schneeweiss","year":"2005","unstructured":"Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol. 2005;58:323\u201337.","journal-title":"J Clin Epidemiol"},{"key":"1548_CR32","doi-asserted-by":"publisher","first-page":"204209861986474","DOI":"10.1177\/2042098619864744","volume":"10","author":"A Bate","year":"2019","unstructured":"Bate A, Hornbuckle K, Juhaeri J, Motsko SP, Reynolds RF. Hypothesis-free signal detection in healthcare databases: finding its value for pharmacovigilance. Ther Adv Drug Saf. 2019;10:2042098619864744.","journal-title":"Ther Adv Drug Saf."},{"key":"1548_CR33","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1002\/pds.3197","volume":"21","author":"PM Coloma","year":"2012","unstructured":"Coloma PM, Trifir\u00f2 G, Schuemie MJ, Gini R, Herings R, Hippisley-Cox J, et al. Electronic healthcare databases for active drug safety surveillance: is there enough leverage? Pharmacoepidemiol Drug Saf. 2012;21:611\u201321.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR34","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/jamia\/ocad247","volume":"31","author":"C Reich","year":"2024","unstructured":"Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al. OHDSI Standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31:583\u201390.","journal-title":"J Am Med Inform Assoc"},{"key":"1548_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40264-016-0405-1","volume":"39","author":"AFZ Wisniewski","year":"2016","unstructured":"Wisniewski AFZ, Bate A, Bousquet C, Brueckner A, Candore G, Juhlin K, et al. Good signal detection practices: evidence from IMI PROTECT. Drug Saf. 2016;39:469\u201390.","journal-title":"Drug Saf"},{"key":"1548_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/pds.2053","volume":"20","author":"PM Coloma","year":"2011","unstructured":"Coloma PM, Schuemie MJ, Trifir\u00f2 G, Gini R, Herings R, Hippisley-Cox J, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011;20:1\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR37","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s10618-009-0152-3","volume":"20","author":"GN Nor\u00e9n","year":"2010","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20:361\u201387.","journal-title":"Data Min Knowl Discov"},{"key":"1548_CR38","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/joim.12159","volume":"275","author":"G Trifir\u00f2","year":"2014","unstructured":"Trifir\u00f2 G, Coloma PM, Rijnbeek PR, Romio S, Mosseveld B, Weibel D, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014;275:551\u201361.","journal-title":"J Intern Med"},{"key":"1548_CR39","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40264-018-0640-8","volume":"41","author":"E Whalen","year":"2018","unstructured":"Whalen E, Hauben M, Bate A. Time series disturbance detection for hypothesis-free signal detection in longitudinal observational databases. Drug Saf. 2018;41:565\u201377.","journal-title":"Drug Saf"},{"key":"1548_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s40264-017-0626-y","volume":"41","author":"X Zhou","year":"2018","unstructured":"Zhou X, Douglas IJ, Shen R, Bate A. Signal detection for recently approved products: adapting and evaluating self-controlled case series method using a US claims and UK electronic medical records database. Drug Saf. 2018;41:523\u201336.","journal-title":"Drug Saf"},{"key":"1548_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s40264-013-0132-9","volume":"37","author":"C Ferrajolo","year":"2014","unstructured":"Ferrajolo C, Coloma PM, Verhamme KMC, Schuemie MJ, de Bie S, Gini R, et al. Signal detection of potentially drug-induced acute liver injury in children using a multi-country healthcare database network. Drug Saf. 2014;37:99\u2013108.","journal-title":"Drug Saf"},{"key":"1548_CR42","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/pds.5512","volume":"32","author":"EA Suarez","year":"2023","unstructured":"Suarez EA, Nguyen M, Zhang D, Zhao Y, Stojanovic D, Munoz M, et al. Novel methods for pregnancy drug safety surveillance in the FDA Sentinel System. Pharmacoepidemiol Drug Saf. 2023;32:126\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR43","unstructured":"Sentinel. Outcome monitoring following Ozempic use in patients with type 2 diabetes: a signal identification analysis. 2022. https:\/\/www.sentinelinitiative.org\/studies\/drugs\/individual-drug-analyses\/outcome-monitoring-following-ozempic-use-patients-type-2."},{"key":"1548_CR44","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/pds.3423","volume":"22","author":"M Kulldorff","year":"2013","unstructured":"Kulldorff M, Dashevsky I, Avery TR, Chan AK, Davis RL, Graham D, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22:517\u201323.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR45","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s40264-015-0341-5","volume":"38","author":"AC Pacurariu","year":"2015","unstructured":"Pacurariu AC, Straus SM, Trifir\u00f2 G, Schuemie MJ, Gini R, Herings R, et al. Useful interplay between spontaneous ADR reports and electronic healthcare records in signal detection. Drug Saf. 2015;38:1201\u201310.","journal-title":"Drug Saf"},{"key":"1548_CR46","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3389\/fphar.2018.00594","volume":"9","author":"VK Patadia","year":"2018","unstructured":"Patadia VK, Schuemie MJ, Coloma PM, Herings R, van der Lei J, Sturkenboom M, et al. Can electronic health records databases complement spontaneous reporting system databases? A historical-reconstruction of the association of rofecoxib and acute myocardial infarction. Front Pharmacol. 2018;9:594.","journal-title":"Front Pharmacol"},{"key":"1548_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.2337\/dc17-0476","volume":"41","author":"S Toh","year":"2018","unstructured":"Toh S, Reichman ME, Graham DJ, Hampp C, Zhang R, Butler MG, et al. Prospective postmarketing surveillance of acute myocardial infarction in new users of saxagliptin: a population-based study. Diabetes Care. 2018;41:39\u201348.","journal-title":"Diabetes Care"},{"key":"1548_CR48","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/pds.4375","volume":"27","author":"EA Chrischilles","year":"2018","unstructured":"Chrischilles EA, Gagne JJ, Fireman B, Nelson J, Toh S, Shoaibi A, et al. Prospective surveillance pilot of rivaroxaban safety within the US Food and Drug Administration Sentinel System. Pharmacoepidemiol Drug Saf. 2018;27:263\u201371.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR49","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1093\/aje\/kwab034","volume":"190","author":"SV Wang","year":"2021","unstructured":"Wang SV, Maro JC, Gagne JJ, Patorno E, Kattinakere S, Stojanovic D, et al. A general propensity score for signal identification using tree-based scan statistics. Am J Epidemiol. 2021;190:1424\u201333.","journal-title":"Am J Epidemiol"},{"key":"1548_CR50","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00228-006-0181-4","volume":"62","author":"M Hauben","year":"2006","unstructured":"Hauben M, Reich L, Van Puijenbroek EP, Gerrits CM, Patadia VK. Data mining in pharmacovigilance: lessons from phantom ships. Eur J Clin Pharmacol. 2006;62:967\u201370.","journal-title":"Eur J Clin Pharmacol"},{"key":"1548_CR51","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40264-024-01422-8","volume":"47","author":"M Gordillo-Mara\u00f1\u00f3n","year":"2024","unstructured":"Gordillo-Mara\u00f1\u00f3n M, Candore G, Hedenmalm K, Browne K, Flynn R, Piccolo L, et al. Lessons learned on observed-to-expected analysis using spontaneous reports during mass vaccination. Drug Saf. 2024;47:607\u201315.","journal-title":"Drug Saf"},{"key":"1548_CR52","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1111\/bcp.13056","volume":"82","author":"JM Luteijn","year":"2016","unstructured":"Luteijn JM, Morris JK, Garne E, Given J, de Jong-van den Berg L, Addor M-C, et al. EUROmediCAT signal detection: a systematic method for identifying potential teratogenic medication. Br J Clin Pharmacol. 2016;82:1110\u201322.","journal-title":"Br J Clin Pharmacol"},{"key":"1548_CR53","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/pds.5610","volume":"32","author":"MDX van der Boom","year":"2023","unstructured":"van der Boom MDX, van Eekeren R, van Hunsel FPAM. Observed-over-expected analysis as additional method for pharmacovigilance signal detection in large-scaled spontaneous adverse event reporting. Pharmacoepidemiol Drug Saf. 2023;32:783\u201394.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR54","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092\u2013101.","journal-title":"N Engl J Med"},{"key":"1548_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/pds.3918","volume":"25","author":"O Mahaux","year":"2016","unstructured":"Mahaux O, Bauchau V, Van Holle L. Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines. Pharmacoepidemiol Drug Saf. 2016;25:215\u201322.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR56","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","volume":"38","author":"MH Noe","year":"2020","unstructured":"Noe MH, Micheletti RG. Diagnosis and management of Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis. Clin Dermatol. 2020;38:607\u201312.","journal-title":"Clin Dermatol"},{"key":"1548_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1435","volume":"373","author":"X Li","year":"2021","unstructured":"Li X, Ostropolets A, Makadia R, Shoaibi A, Rao G, Sena AG, et al. Characterising the background incidence rates of adverse events of special interest for COVID-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373: n1435.","journal-title":"BMJ"},{"key":"1548_CR58","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.vaccine.2022.11.031","volume":"41","author":"C Willame","year":"2023","unstructured":"Willame C, Dodd C, Dur\u00e1n CE, Elbers R, Gini R, Bartolini C, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases\u2014an ACCESS cohort study. Vaccine. 2023;41:251\u201362.","journal-title":"Vaccine"},{"key":"1548_CR59","unstructured":"Brighton collaboration. Case definitions. 2024. https:\/\/brightoncollaboration.org\/case-definitions\/."},{"key":"1548_CR60","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/cpt.2828","volume":"113","author":"J Durand","year":"2023","unstructured":"Durand J, Dogn\u00e9 J-M, Cohet C, Browne K, Gordillo-Mara\u00f1\u00f3n M, Piccolo L, et al. Safety monitoring of COVID-19 vaccines: perspective from the European Medicines Agency. Clin Pharmacol Ther. 2023;113:1223\u201334.","journal-title":"Clin Pharmacol Ther"},{"key":"1548_CR61","unstructured":"Food and Drug Administration. FAERS quarterly data files documentation. 2015. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/faers-quarterly-data-files-documentation."},{"issue":"Suppl C","key":"1548_CR62","doi-asserted-by":"publisher","first-page":"C40","DOI":"10.1016\/S0149-2918(98)80007-6","volume":"20","author":"SA Goldman","year":"1998","unstructured":"Goldman SA. Limitations and strengths of spontaneous reports data. Clin Ther. 1998;20(Suppl C):C40-44.","journal-title":"Clin Ther"},{"key":"1548_CR63","first-page":"409","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. VigiBase, the WHO Global ICSR database system: basic facts. Ther Innov Regul Sci. 2008;42:409\u201319.","journal-title":"Ther Innov Regul Sci."},{"key":"1548_CR64","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/jcph.3","volume":"53","author":"M Petronijevic","year":"2013","unstructured":"Petronijevic M, Ilic K. Associations of gender and age with the reporting of drug-induced hepatic failure: data from the VigiBaseTM. J Clin Pharmacol. 2013;53:435\u201343.","journal-title":"J Clin Pharmacol"},{"key":"1548_CR65","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40264-020-00957-w","volume":"43","author":"L Sandberg","year":"2020","unstructured":"Sandberg L, Taavola H, Aoki Y, Chandler R, Nor\u00e9n GN. Risk factor considerations in statistical signal detection: using subgroup disproportionality to uncover risk groups for adverse drug reactions in VigiBase. Drug Saf. 2020;43:999\u20131009.","journal-title":"Drug Saf"},{"key":"1548_CR66","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s40264-023-01306-3","volume":"46","author":"O Mahaux","year":"2023","unstructured":"Mahaux O, Powell G, Haguinet F, Sobczak P, Saini N, Barry A, et al. Identifying safety subgroups at risk: assessing the agreement between statistical alerting and patient subgroup risk. Drug Saf. 2023;46:601\u201314.","journal-title":"Drug Saf"},{"key":"1548_CR67","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.2165\/00002018-200831110-00008","volume":"31","author":"J Hopstadius","year":"2008","unstructured":"Hopstadius J, Nor\u00e9n GN, Bate A, Edwards IR. Impact of stratification on adverse drug reaction surveillance. Drug Saf. 2008;31:1035\u201348.","journal-title":"Drug Saf"},{"key":"1548_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40264-024-01473-x","volume":"48","author":"Y Noguchi","year":"2025","unstructured":"Noguchi Y, Tachi T, Yoshimura T. Caveats of covariate adjustment in disproportionality analysis for best practices. Drug Saf. 2025;48:1\u20135.","journal-title":"Drug Saf"},{"key":"1548_CR69","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1471-2288-14-17","volume":"14","author":"F Leroy","year":"2014","unstructured":"Leroy F, Dauxois J-Y, Th\u00e9ophile H, Haramburu F, Tubert-Bitter P. Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases. BMC Med Res Methodol. 2014;14:17.","journal-title":"BMC Med Res Methodol"},{"key":"1548_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","volume":"31","author":"TB Agbabiaka","year":"2008","unstructured":"Agbabiaka TB, Savovi\u0107 J, Ernst E. Methods for causality assessment of adverse drug reactions. Drug-Safety. 2008;31:21\u201337.","journal-title":"Drug-Safety."},{"key":"1548_CR71","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/pds.4115","volume":"25","author":"JHG Scholl","year":"2016","unstructured":"Scholl JHG, van Puijenbroek EP. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands. Pharmacoepidemiol Drug Saf. 2016;25:1361\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR72","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/pds.4790","volume":"28","author":"JHG Scholl","year":"2019","unstructured":"Scholl JHG, van Hunsel FPAM, Hak E, van Puijenbroek EP. Time to onset in statistical signal detection revisited: a follow-up study in long-term onset adverse drug reactions. Pharmacoepidemiol Drug Saf. 2019;28:1283\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR73","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1002\/pds.1072","volume":"14","author":"R Edwards","year":"2005","unstructured":"Edwards R, Faich G, Tilson H, International Society of Pharmacovigilance. Points to consider: the roles of surveillance and epidemiology in advancing drug safety. Pharmacoepidemiol Drug Saf. 2005;14:665\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR74","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cpt.320","volume":"99","author":"R Ball","year":"2016","unstructured":"Ball R, Robb M, Anderson SA, Dal Pan G. The FDA\u2019s sentinel initiative\u2014a comprehensive approach to medical product surveillance. Clin Pharmacol Ther. 2016;99:265\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"1548_CR75","unstructured":"Mini-Sentinel Medical Product Assessment. A protocol for assessment of Dabigatran. 2015. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/Drugs\/Assessments\/Mini-Sentinel_Protocol-for-Assessment-of-Dabigatran_0.pdf."},{"key":"1548_CR76","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1056\/NEJMp1302834","volume":"368","author":"MR Southworth","year":"2013","unstructured":"Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarketing reports of bleeding. N Engl J Med. 2013;368:1272\u20134.","journal-title":"N Engl J Med"},{"key":"1548_CR77","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581\u20138.","journal-title":"N Engl J Med"},{"key":"1548_CR78","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM199809103391102","volume":"339","author":"H Jick","year":"1998","unstructured":"Jick H, Vasilakis C, Weinrauch LA, Meier CR, Jick SS, Derby LE. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 1998;339:719\u201324.","journal-title":"N Engl J Med"},{"key":"1548_CR79","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1056\/NEJM199809103391101","volume":"339","author":"MA Khan","year":"1998","unstructured":"Khan MA, Herzog CA, St Peter JV, Hartley GG, Madlon-Kay R, Dick CD, et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. N Engl J Med. 1998;339:713\u20138.","journal-title":"N Engl J Med"},{"key":"1548_CR80","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1002\/phar.2468","volume":"40","author":"M Mohamoud","year":"2020","unstructured":"Mohamoud M, Horgan C, Eworuke E, Dee E, Bohn J, Shapira O, et al. Complementary use of US FDA\u2019s Adverse Event Reporting System and Sentinel System to characterize direct oral anticoagulants-associated cutaneous small vessel vasculitis. Pharmacotherapy. 2020;40:1099\u2013107.","journal-title":"Pharmacotherapy"},{"key":"1548_CR81","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1002\/pds.5514","volume":"31","author":"A Ajao","year":"2022","unstructured":"Ajao A, Cosgrove A, Eworuke E, Mohamoud M, Zhang R, Shapira O, et al. A cohort study to assess risk of cutaneous small vessel vasculitis among users of different oral anticoagulants. Pharmacoepidemiol Drug Saf. 2022;31:1164\u201373.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR82","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/pds.5022","volume":"29","author":"RE Chandler","year":"2020","unstructured":"Chandler RE. Nintedanib and ischemic colitis: signal assessment with the integrated use of two types of real-world evidence, spontaneous reports of suspected adverse drug reactions, and observational data from large health-care databases. Pharmacoepidemiol Drug Saf. 2020;29:951\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR83","doi-asserted-by":"crossref","unstructured":"Li X, Burn E, Duarte-Salles T, Yin C, Reich C, Delmestri A, et al. Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different COVID-19 vaccines: international network cohort study from five European countries and the US. BMJ. 2022:e071594.","DOI":"10.1136\/bmj-2022-071594"},{"key":"1548_CR84","unstructured":"Darwin EU. Standardised analytics. 2023. https:\/\/darwin-eu.org\/index.php\/methods\/standardised-analytics."},{"key":"1548_CR85","unstructured":"Darwin EU. Coordination Centre. 2023. https:\/\/darwin-eu.org\/index.php\/about\/coordination-centre."},{"key":"1548_CR86","doi-asserted-by":"crossref","unstructured":"Golder S, Xu D, O\u2019Connor K, Wang Y, Batra M, Hernandez GG. Leveraging natural language processing and machine learning methods for adverse drug event detection in electronic health\/medical records: a scoping review. Drug Saf. 2025;48(4):321\u201337.","DOI":"10.1007\/s40264-024-01505-6"},{"key":"1548_CR87","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/PTS.0000000000000104","volume":"13","author":"WM Marella","year":"2017","unstructured":"Marella WM, Sparnon E, Finley E. Screening electronic health record-related patient safety reports using machine learning. J Patient Saf. 2017;13:31\u20136.","journal-title":"J Patient Saf"},{"key":"1548_CR88","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1177\/1460458219833102","volume":"26","author":"HP Evans","year":"2020","unstructured":"Evans HP, Anastasiou A, Edwards A, Hibbert P, Makeham M, Luz S, et al. Automated classification of primary care patient safety incident report content and severity using supervised machine learning (ML) approaches. Health Inform J. 2020;26:3123\u201339.","journal-title":"Health Inform J"},{"key":"1548_CR89","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40264-015-0278-8","volume":"38","author":"VG Koutkias","year":"2015","unstructured":"Koutkias VG, Jaulent M-C. Computational approaches for pharmacovigilance signal detection: toward integrated and semantically-enriched frameworks. Drug Saf. 2015;38:219\u201332.","journal-title":"Drug Saf"},{"key":"1548_CR90","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10916-024-02070-2","volume":"48","author":"H Abedian Kalkhoran","year":"2024","unstructured":"Abedian Kalkhoran H, Zwaveling J, van Hunsel F, Kant A. An innovative method to strengthen evidence for potential drug safety signals using Electronic Health Records. J Med Syst. 2024;48:51.","journal-title":"J Med Syst"},{"key":"1548_CR91","doi-asserted-by":"publisher","first-page":"ooaf003","DOI":"10.1093\/jamiaopen\/ooaf003","volume":"8","author":"JL Painter","year":"2025","unstructured":"Painter JL, Chalamalasetti VR, Kassekert R, Bate A. Automating pharmacovigilance evidence generation: using large language models to produce context-aware structured query language. JAMIA Open. 2025;8:ooaf003.","journal-title":"JAMIA Open."},{"key":"1548_CR92","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1002\/pds.5553","volume":"31","author":"HR Gosselt","year":"2022","unstructured":"Gosselt HR, Bazelmans EA, Lieber T, van Hunsel FPAM, H\u00e4rmark L. Development of a multivariate prediction model to identify individual case safety reports which require clinical review. Pharmacoepidemiol Drug Saf. 2022;31:1300\u20137.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR93","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40264-022-01153-8","volume":"45","author":"GL Martin","year":"2022","unstructured":"Martin GL, Jouganous J, Savidan R, Bellec A, Goehrs C, Benkebil M, et al. Validation of artificial intelligence to support the automatic coding of patient adverse drug reaction reports, using nationwide pharmacovigilance data. Drug Saf. 2022;45:535\u201348.","journal-title":"Drug Saf"},{"key":"1548_CR94","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.therap.2022.11.004","volume":"78","author":"A Pariente","year":"2023","unstructured":"Pariente A, Micallef J, Lahouegue A, Molimard M, Auffret M, Chouchana L, et al. What place for intelligent automation and artificial intelligence to preserve and strengthen vigilance expertise in the face of increasing declarations? Therapie. 2023;78:131\u201343.","journal-title":"Therapie"},{"key":"1548_CR95","first-page":"CAT.23.0404","volume":"5","author":"AA Tierney","year":"2024","unstructured":"Tierney AA, Gayre G, Hoberman B, Mattern B, Ballesca M, Kipnis P, et al. Ambient artificial intelligence scribes to alleviate the burden of clinical documentation. NEJM Catal. 2024;5:CAT.23.0404.","journal-title":"NEJM Catal."},{"key":"1548_CR96","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/pds.2027","volume":"19","author":"JA Linder","year":"2010","unstructured":"Linder JA, Haas JS, Iyer A, Labuzetta MA, Ibara M, Celeste M, et al. Secondary use of electronic health record data: spontaneous triggered adverse drug event reporting. Pharmacoepidemiol Drug Saf. 2010;19:1211\u20135.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR97","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/pds.5162","volume":"30","author":"J Januskiene","year":"2021","unstructured":"Januskiene J, Segec A, Slattery J, Genov G, Plueschke K, Kurz X, et al. What are the patients\u2019 and health care professionals\u2019 understanding and behaviors towards adverse drug reaction reporting and additional monitoring? Pharmacoepidemiol Drug Saf. 2021;30:334\u201341.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR98","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"},{"key":"1548_CR99","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s43441-024-00711-9","volume":"59","author":"G Powell","year":"2025","unstructured":"Powell G, Kara V, Naranjo D, Kulkarni M, Best-Sule K, Coster T, et al. Testing the feasibility of a digital point of care solution for the trusted near real-time bidirectional exchange of novel and informative adverse event information. Ther Innov Regul Sci. 2025;59:124\u201334.","journal-title":"Ther Innov Regul Sci."},{"key":"1548_CR100","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/pds.3223","volume":"21","author":"S Brajovic","year":"2012","unstructured":"Brajovic S, Piazza-Hepp T, Swartz L, Dal Pan G. Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration. Pharmacoepidemiol Drug Saf. 2012;21:565\u201370 (discussion 571\u2013572).","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1548_CR101","unstructured":"European Medicines Agency (EMA). Reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-reflection-paper-use-artificial-intelligence-ai-medicinal-product-lifecycle_en.pdf."},{"key":"1548_CR102","unstructured":"Sentinel. Exploration of potential for Sentinel and PCORnet data linkage. 2015. https:\/\/www.sentinelinitiative.org\/about\/how-sentinel-gets-its-data\/exploration-potential-sentinel-and-pcornet-data-linkage."},{"key":"1548_CR103","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1007\/s43441-020-00130-6","volume":"54","author":"O Lagerlund","year":"2020","unstructured":"Lagerlund O, Strese S, Fladvad M, Lindquist M. WHODrug: a global, validated and updated dictionary for medicinal information. Ther Innov Regul Sci. 2020;54:1116\u201322.","journal-title":"Ther Innov Regul Sci."},{"key":"1548_CR104","unstructured":"European Medicines Agency (EMA). ICH E2B (R3) electronic transmission of individual case safety reports (ICSRs)\u2014data elements and message specification\u2014implementation guide\u2014scientific guideline. https:\/\/www.ema.europa.eu\/en\/ich-e2b-r3-electronic-transmission-individual-case-safety-reports-icsrs-data-elements-message-specification-implementation-guide-scientific-guideline."},{"key":"1548_CR105","unstructured":"European Medicines Agency (EMA). Legal framework: pharmacovigilance. 2015. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/pharmacovigilance-overview\/legal-framework-pharmacovigilance."},{"key":"1548_CR106","unstructured":"European Medicines Agency (EMA). Implementation of the pharmacovigilance legislation. 2023. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/pharmacovigilance-overview\/legal-framework-pharmacovigilance\/implementation-pharmacovigilance-legislation."},{"key":"1548_CR107","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/jamia\/ocv038","volume":"22","author":"AN Kho","year":"2015","unstructured":"Kho AN, Cashy JP, Jackson KL, Pah AR, Goel S, Boehnke J, et al. Design and implementation of a privacy preserving electronic health record linkage tool in Chicago. J Am Med Inform Assoc. 2015;22:1072\u201380.","journal-title":"J Am Med Inform Assoc"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-025-01548-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-025-01548-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T12:06:42Z","timestamp":1757160402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-025-01548-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,13]]},"references-count":107,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["1548"],"URL":"https:\/\/doi.org\/10.1007\/s40264-025-01548-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,13]]},"assertion":[{"value":"25 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Universit\u00e0 degli Studi di Verona within the CRUI-CARE Agreement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G.T. has served, over the last 3 years, on advisory boards\/seminars funded by Sanofi, MSD, Eli Lilly, Sobi, Celgene, Daiichi Sankyo, Novo Nordisk, Gilead, and Amgen on topics not related to content of this paper; he is also a scientific coordinator of the academic spin-off \u201cINSPIRE srl,\u201d which has received funding from several pharmaceutical companies (Kiowa Kirin, Shionogi, Shire, Novo Nordisk, and Daiichi Sankyo) for conducting observational studies and additional consultancy services on topics not related to content of this paper. In addition, he is currently a consultant for Viatris in a legal case concerning an adverse reaction to sertraline. G.C. is a full-time employee of Bayer AG. A.B. is an employee of GSK and holds both stock and stock options with GSK. J.S.B. is an employee of TriNetX, LLC. T.A.H. is an employee at Takeda Pharmaceutical, United States. When the project started, M.S. was an employee at Daiichi Sankyo Inc. but currently, she is an employee at Bayer Inc. and receives stocks from the organization. However, the organization did not sponsor this manuscript, and the views expressed in this document do not represent the organization. A.Se. is an employee of the European Medicines Agency. A.B., G.N.N., S.S., M.T., E.v.P., and G.T. are Editorial Board members of Drug Safety, but were not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. The other authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the article apart from those disclosed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This study does not involve any human or animal subjects, or any sensitive information.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable, as this study does not involve any human participants.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable, as this study does not involve any individual data or images that would require consent for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Data sharing does not apply to this article as no datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable, as no custom code or software application was developed or used in this study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"S.C.: writing\u2014original draft, writing\u2014review and editing, and visualization. A.B.: writing\u2014review and editing. J.S.B.: writing\u2014review and editing. G.C.: writing\u2014review and editing. R.E.C.: writing\u2014review and editing. T.A.H.: writing\u2014review and editing. S.L.: writing\u2014review and editing. J.C.M.: writing\u2014review and editing. G.N.N.: writing\u2014review and editing. A.P.: writing\u2014review and editing. M.R.: writing\u2014review and editing. M.S.: writing\u2014review and editing. A.Se.: writing\u2014review and editing. S.S.: writing\u2014review and editing. A.Sp.: writing\u2014review and editing. S.T.: writing\u2014review and editing. M.T.: writing\u2014review and editing. E.v.P.: writing\u2014review and editing. G.T.: writing\u2014original draft, writing\u2014review and editing, supervision, and conceptualization. All authors read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}